Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

NCT01757015 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: NVA237
DRUG: Placebo to NVA237

Sponsor

Novartis Pharmaceuticals